Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1988 Jan;63(1):10–16. doi: 10.1136/adc.63.1.10

Surfactant treatment and incidence of intraventricular haemorrhage in severe respiratory distress syndrome.

F B McCord 1, T Curstedt 1, H L Halliday 1, G McClure 1, M M Reid 1, B Robertson 1
PMCID: PMC1779311  PMID: 3279916

Abstract

As part of a multicentre study of porcine surfactant administration in respiratory distress syndrome, 29 babies weighing 2000 g or less were studied in the neonatal intensive care unit of the Royal Maternity Hospital, Belfast. Fourteen babies of a mean gestational age of 28.1 weeks were randomly allocated to the treatment group (200 mg/kg phospholipid given intratracheally) and 15 babies of a mean gestational age of 28.7 weeks formed the control group. All babies had severe respiratory distress syndrome (oxygen requirement over 60%, mechanical ventilation, and age 15 hours or less). Almost immediate improvement in oxygenation was seen in the treated group so that oxygen concentrations could be reduced and remained significantly lower than those of control babies for the first seven days of life. Alveolar-arterial oxygen gradients were also significantly different for the first five days after treatment. More babies in the treatment group survived (79% v 40%) but the difference was not significant. The incidence of pneumothorax and of intraventricular haemorrhage, however, was significantly lower in treated babies compared with controls. For babies weighing less than 1200 g the risk of developing or extending intraventricular haemorrhage after entry to the study was also reduced in the treatment group (29% v 100%).

Full text

PDF
16

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Edwards D. K., Hilton S. V., Merritt T. A., Hallman M., Mannino F., Boynton B. R. Respiratory distress syndrome treated with human surfactant: radiographic findings. Radiology. 1985 Nov;157(2):329–334. doi: 10.1148/radiology.157.2.3840268. [DOI] [PubMed] [Google Scholar]
  2. Enhorning G., Shennan A., Possmayer F., Dunn M., Chen C. P., Milligan J. Prevention of neonatal respiratory distress syndrome by tracheal instillation of surfactant: a randomized clinical trial. Pediatrics. 1985 Aug;76(2):145–153. [PubMed] [Google Scholar]
  3. Fujiwara T., Maeta H., Chida S., Morita T., Watabe Y., Abe T. Artificial surfactant therapy in hyaline-membrane disease. Lancet. 1980 Jan 12;1(8159):55–59. doi: 10.1016/s0140-6736(80)90489-4. [DOI] [PubMed] [Google Scholar]
  4. Giedion A., Haefliger H., Dangel P. Acute pulmonary X-ray changes in hyaline membrane disease treated with artificial ventilation and positive end-expiratory pressure (PEP). Pediatr Radiol. 1973 Oct;1(3):145–152. doi: 10.1007/BF00974058. [DOI] [PubMed] [Google Scholar]
  5. Gitlin J. D., Soll R. F., Parad R. B., Horbar J. D., Feldman H. A., Lucey J. F., Taeusch H. W. Randomized controlled trial of exogenous surfactant for the treatment of hyaline membrane disease. Pediatrics. 1987 Jan;79(1):31–37. [PubMed] [Google Scholar]
  6. Greenough A., Wood S., Morley C. J., Davis J. A. Pancuronium prevents pneumothoraces in ventilated premature babies who actively expire against positive pressure inflation. Lancet. 1984 Jan 7;1(8367):1–3. doi: 10.1016/s0140-6736(84)90177-6. [DOI] [PubMed] [Google Scholar]
  7. Halliday H. L., Hirata T., Brady J. P. Echocardiographic findings of large patent ductus arteriosus in the very low birthweight infant before and after treatment with indomethacin. Arch Dis Child. 1979 Oct;54(10):744–749. doi: 10.1136/adc.54.10.744. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Halliday H. L., McClure G., Reid M. M. Growth and development two years after artificial surfactant replacement at birth. Early Hum Dev. 1986 Jun;13(3):323–327. doi: 10.1016/0378-3782(86)90067-8. [DOI] [PubMed] [Google Scholar]
  9. Halliday H. L., McClure G., Reid M. M., Lappin T. R., Meban C., Thomas P. S. Controlled trial of artificial surfactant to prevent respiratory distress syndrome. Lancet. 1984 Mar 3;1(8375):476–478. doi: 10.1016/s0140-6736(84)92849-6. [DOI] [PubMed] [Google Scholar]
  10. Halliday H., Robertson B., Nilsson R., Rigaut J. P., Grossmann G. Automated image analysis of alveolar expansion patterns in immature newborn rabbits treated with natural or artificial surfactant. Br J Exp Pathol. 1987 Oct;68(5):727–732. [PMC free article] [PubMed] [Google Scholar]
  11. Hallman M., Merritt T. A., Jarvenpaa A. L., Boynton B., Mannino F., Gluck L., Moore T., Edwards D. Exogenous human surfactant for treatment of severe respiratory distress syndrome: a randomized prospective clinical trial. J Pediatr. 1985 Jun;106(6):963–969. doi: 10.1016/s0022-3476(85)80253-5. [DOI] [PubMed] [Google Scholar]
  12. Hallman M., Merritt T. A., Schneider H., Epstein B. L., Mannino F., Edwards D. K., Gluck L. Isolation of human surfactant from amniotic fluid and a pilot study of its efficacy in respiratory distress syndrome. Pediatrics. 1983 Apr;71(4):473–482. [PubMed] [Google Scholar]
  13. Hill A., Perlman J. M., Volpe J. J. Relationship of pneumothorax to occurrence of intraventricular hemorrhage in the premature newborn. Pediatrics. 1982 Feb;69(2):144–149. [PubMed] [Google Scholar]
  14. Kwong M. S., Egan E. A., Notter R. H., Shapiro D. L. Double-blind clinical trial of calf lung surfactant extract for the prevention of hyaline membrane disease in extremely premature infants. Pediatrics. 1985 Oct;76(4):585–592. [PubMed] [Google Scholar]
  15. Lipscomb A. P., Thorburn R. J., Reynolds E. O., Stewart A. L., Blackwell R. J., Cusick G., Whitehead M. D. Pneumothorax and cerebral haemorrhage in preterm infants. Lancet. 1981 Feb 21;1(8217):414–416. doi: 10.1016/s0140-6736(81)91794-3. [DOI] [PubMed] [Google Scholar]
  16. Lupton B., Halliday H., Thomas P., McClure G., Reid M. M. Chronic lung disease in a neonatal intensive care unit: 8 years experience. Ir Med J. 1987 Sep;80(9):254–257. [PubMed] [Google Scholar]
  17. Merritt T. A., Hallman M., Bloom B. T., Berry C., Benirschke K., Sahn D., Key T., Edwards D., Jarvenpaa A. L., Pohjavuori M. Prophylactic treatment of very premature infants with human surfactant. N Engl J Med. 1986 Sep 25;315(13):785–790. doi: 10.1056/NEJM198609253151301. [DOI] [PubMed] [Google Scholar]
  18. Noack G., Berggren P., Curstedt T., Grossmann G., Herin P., Mortensson W., Nilsson R., Robertson B. Severe neonatal respiratory distress syndrome treated with the isolated phospholipid fraction of natural surfactant. Acta Paediatr Scand. 1987 Sep;76(5):697–705. doi: 10.1111/j.1651-2227.1987.tb10552.x. [DOI] [PubMed] [Google Scholar]
  19. Northway W. H., Jr, Rosan R. C. Radiographic features of pulmonary oxygen toxicity in the newborn: Bronchopulmonary dysplasia. Radiology. 1968 Jul;91(1):49–58. doi: 10.1148/91.1.49. [DOI] [PubMed] [Google Scholar]
  20. Pape K. E., Blackwell R. J., Cusick G., Sherwood A., Houang M. T., Thorburn R. J., Reynolds E. O. Ultrasound detection of brain damage in preterm infants. Lancet. 1979 Jun 16;1(8129):1261–1264. doi: 10.1016/s0140-6736(79)92227-x. [DOI] [PubMed] [Google Scholar]
  21. Papile L. A., Burstein J., Burstein R., Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr. 1978 Apr;92(4):529–534. doi: 10.1016/s0022-3476(78)80282-0. [DOI] [PubMed] [Google Scholar]
  22. Raju T. N., Vidyasagar D., Bhat R., Sobel D., McCulloch K. M., Anderson M., Maeta H., Levy P. S., Furner S. Double-blind controlled trial of single-dose treatment with bovine surfactant in severe hyaline membrane disease. Lancet. 1987 Mar 21;1(8534):651–656. doi: 10.1016/s0140-6736(87)90414-4. [DOI] [PubMed] [Google Scholar]
  23. Shapiro D. L., Notter R. H., Morin F. C., 3rd, Deluga K. S., Golub L. M., Sinkin R. A., Weiss K. I., Cox C. Double-blind, randomized trial of a calf lung surfactant extract administered at birth to very premature infants for prevention of respiratory distress syndrome. Pediatrics. 1985 Oct;76(4):593–599. [PubMed] [Google Scholar]
  24. Smyth J. A., Metcalfe I. L., Duffty P., Possmayer F., Bryan M. H., Enhorning G. Hyaline membrane disease treated with bovine surfactant. Pediatrics. 1983 Jun;71(6):913–917. [PubMed] [Google Scholar]
  25. Thorburn R. J., Lipscomb A. P., Stewart A. L., Reynolds E. O., Hope P. L., Pape K. E. Prediction of death and major handicap in very preterm infants by brain ultrasound. Lancet. 1981 May 23;1(8230):1119–1121. doi: 10.1016/s0140-6736(81)92295-9. [DOI] [PubMed] [Google Scholar]
  26. Wigglesworth J. S., Keith I. H., Girling D. J., Slade S. A. Hyaline membrane disease, alkali, and intraventricular haemorrhage. Arch Dis Child. 1976 Oct;51(10):755–762. doi: 10.1136/adc.51.10.755. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Wilkinson A., Jenkins P. A., Jeffrey J. A. Two controlled trials of dry artificial surfactant: early effects and later outcome in babies with surfactant deficiency. Lancet. 1985 Aug 10;2(8450):287–291. doi: 10.1016/s0140-6736(85)90346-0. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES